TG Therapeutics
TGTX
101 hedge funds and large institutions have $422M invested in TG Therapeutics in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 35 increasing their positions, 25 reducing their positions, and 11 closing their positions.
79% more call options, than puts
Call options by funds: $9.23M | Put options by funds: $5.16M
40% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 25
22% more capital invested
Capital invested by funds: $345M → $422M (+$76.9M)
0.31% more ownership
Funds ownership: 51.43% → 51.74% (+0.31%)
5% less funds holding
Funds holding: 106 → 101 (-5)
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BM
Bridger Management
New York
|
+$7.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$6.99M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.46M |
| 4 |
Charles Schwab
San Francisco,
California
|
+$1.77M |
| 5 |
CCI
Columbus Circle Investors
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UONDDL
University of Notre Dame du Lac
South Bend,
Indiana
|
-$2.13M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$1.64M |
| 3 |
Jennison Associates
New York
|
-$1.22M |
| 4 |
SAM
Senzar Asset Management
New York
|
-$1.21M |
| 5 |
AG
Artal Group
Luxembourg
|
-$1.14M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAM
101
Panagora Asset Management
Boston,
Massachusetts
| – | -$836K | -83,229 | Closed |
|
|
ARTA
102
A.R.T. Advisors
New York
| – | -$582K | -58,000 | Closed |
|
103
Wolverine Trading
Chicago,
Illinois
| – | -$514K | -45,150 | Closed |
|
|
AHB
104
Abner Herrman & Brock
Jersey City,
New Jersey
| – | -$201K | -20,000 | Closed |
|
|
FRM
105
Fox Run Management
Greenwich,
Connecticut
| – | -$156K | -15,500 | Closed |
|
|
SAM
106
Silvercrest Asset Management
New York
| – | -$111K | -11,000 | Closed |
|
107
Creative Planning
Overland Park,
Kansas
| – | -$40K | -4,000 | Closed |
|
|
HH
108
HWG Holdings
Houston,
Texas
| – | -$12.9K | -1,132 | Closed |
|
|
NIT
109
NumerixS Investment Technologies
Vancouver,
British Columbia, Canada
| – | -$8K | -800 | Closed |
|
|
MAM
110
Meeder Asset Management
Dublin,
Ohio
| – | -$3K | -315 | Closed |
|
|
WWM
111
Willingdon Wealth Management
Huntersville,
North Carolina
| – | +$46 | +4 | New |
|
TGTX Hedge Fund Activity: Q3 2017 in Review
101 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q3 2017, worth a combined $422M — up 22% from $345M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TGTX and 7 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 35 added.
The largest buyer was Bridger Management, adding an estimated $7.4M. The largest seller was University of Notre Dame du Lac, exiting entirely with an estimated $2.13M sold.
- 101 institutional investors held TG Therapeutics (TGTX) as of Q3 2017, down from 106 in Q2 2017.
- Funds reported $422M of TG Therapeutics stock for Q3 2017, up 22% quarter-over-quarter.
- 7 funds opened new TG Therapeutics positions in Q3 2017 and 11 closed out, a net change of -4 holders.
- The largest TG Therapeutics buyer in Q3 2017 was Bridger Management, an estimated $7.4M added.
- The largest TG Therapeutics seller in Q3 2017 was University of Notre Dame du Lac, an estimated $2.13M sold.
Based on aggregated 13F filings for Q3 2017.